Supplementary data

Table 2. The 5 most commonly used TKA designs in each country 2000–2016

Norway		Sweden		Finland		Denmark	
design	n	design	n	design	n	design	n
LCS Complete	3,436	NexGen	16,734	Triathlon	12,834	PFC	6,967
Profix	3 319	PFC	12 984	Nexgen	7,515	Nexgen	4,407
Nexgen	3,034	AGC	3,635	PFC	5,168	AGC	3,426
LCS	816	Triathlon	3,393	Duracon	3,995	Vanguard	2,354
Triathlon	757	Vanguard	3,074	Vanguard	2,878	Advance	751

Table 3. The 5 most commonly used TKA designs in the fixation concepts over 2000–2016

Cemented		Uncemented		Hybrid		Inverse hybrid	
design	n	design	n	design	n	design	n
Nexgen	27,948	Nexgen	2,204	PFC	2,248	Nexgen	497
PFC	22,360	Triathlon	1,375	Nexgen	1,629	PFC	10
Triathlon	15,664	PFC	1,221	Profix	906	Triathlon	7
AGC	8,575	Duracon	310	Legion	363	Duracon	5
Vanguard	8,297	Profix	235	AGC	194	Profix	5

Table 9. Proportions of different fixation methods in the Nexgen subgroup during 2000–2016

	Norway	Sweden	Finland	Denmark	Total (%)
Cemented	2,669	15,839	6,471	2,969	25,279 (85)
Uncemented	187	751	698	676	2,312 (8)
Hybrid	177	34	5	1,413	1,629 (5)
Inverse hybrid	1	123	341	32	497 (2)

Table 8. Additional Cox regression covariates with time-dependent coefficients (in different age groups and the Nexgen subgroup)

Factor	Follow-up (years)	Hazard ratio (95% CI)
All patients aged < 65 years		
Female sex	< 1	0.73 (0.66–0.82)
	1–3	1.15 (1.06–1.26)
	3–6	1.35 (1.19–1.52)
	> 6	0.98 (0.86–1.11)
Age per year	< 1	0.96 (0.95–0.97)
	1–3	0.95 (0.94–0.96)
	3–6	0.95 (0.94–0.96)
	> 6	0.95 (0.94–0.96)
Nation		
Norway	< 1	1.51 (1.27–1.79)
	1–3	1.64 (1.44–1.87)
	3–6	1.67 (1.39–2.00)
	> 6	0.98 (0.76–1.25)
Denmark	< 1	1.36 (1.16–1.59)
	1–3	1.53 (1.36–1.73)
	3–6	1.08 (0.90–1.29)
	> 6	1.52 (1.27–1.81)
Finland	< 1	1.32 (1.16–1.51)
	1–3	1.18 (1.06–1.31)
	3–6	1.05 (0.91–1.22)
	> 6	1.35 (1.17–1.56)
Sweden		1.0 reference
Patients aged 55–65 years		
Female sex	< 1.5	0.81 (0.74–0.90)
	1.5–3	1.24 (1.09–1.41)
	3–6	1.33 (1.14–1.54)
	> 6	0.99 (0.85–1.15)
Age		0.96 (0.95–0.97)
Nation		
Denmark		1.40 (1.28–1.53)
Finland		1.23 (1.14–1.33)
Norway		1.50 (1.36–1.66)
Sweden		1.0 reference
Patients aged < 55 years		
Female sex		1.07 (0.96–1.18)
Age		0.96 (0.95–0.97)
Nation		
Denmark	< 1	1.37 (1.01–1.85)
	1–3	1.86 (1.51–2.28)
	3–6	0.83 (0.60–1.16)
	> 6	1.22 (0.90–1.66)
Finland	< 1	1.55 (1.19–2.01)
	1–3	1.30 (1.06–1.58)
	3–6	1.01 (0.77–1.32)
	> 6	0.98 (0.75–1.28)
Norway	< 1	1.52 (1.08–2.13)
	1–3	1.91 (1.51–2.40)
	3–6	1.59 (1.15–2.20)
	> 6	0.81 (0.52–1.30)
Sweden	< 1	1.0 reference
	1–3	1.0 reference
	3–6	1.0 reference
	> 6	1.0 reference
Patients aged < 65 years in the Nexgen subgroup		
Female sex	< 1	0.61 (0.49–0.76)
	1–3	1.43 (1.18–1.72)
	3–6	1.34 (1.01–1.79)
	> 6	1.73 (1.15–2.61)
Age		0.95 (0.94–0.96)
Nation		
Denmark		1.84 (1.57–2.16)
Finland		1.39 (1.20–1.62)
Norway		1.62 (1.29–2.02)
Sweden		1.0 reference